Antibody Candidates
We engage in strategic collaborations to enable the discovery and development of antibodies for prevention, treatment, and cure of infectious diseases.
Pipeline
Anti-HIV-1 CD4bs bNAb
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Authorized
Collaboration: Vir Biotechnology (exclusively licensed to Vir Biotechnology)
Broadly neutralizing anti-HIV V1/V3 antibody
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Authorized
Collaboration: Vir Biotechnology (exclusively licensed to Vir Biotechnology)